Valaciclovir hydrochloride tablet and preparation method thereof

By coating valacyclovir hydrochloride with polyaspartic acid-glutathione cross-linking complex and combining spray granulation and tableting processes, the stability and dissolution of valacyclovir hydrochloride are solved, and rapid dissolution is achieved and high bioavailability, suitable for large-scale production.

CN119033717APending Publication Date: 2024-11-29HAINAN BRIGHT FUTURE PHARMA
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411435101.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-15
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Valacyclovir hydrochloride is prone to moisture absorption and degradation during storage, has poor stability, and the existing preparation methods are difficult to meet the requirements of rapid dissolution and large-scale production.

Method used

Polyaspartic acid-glutathione cross-linking complex coated with valacicocyclovir hydrochloride, and valacicocyclovir hydrochloride tablets were prepared by spray granulation and tableting process, combining colloidal silica and microcrystalline fibers. Materials such as Capsule 101 improve stability and solubility.

Benefits of technology

It significantly improves the stability and bioavailability of valaccyclovir hydrochloride, shortens the disintegration time, ensures complete dissolution within 15 minutes, reduces the content of acyclovir and guanine impurities, and is suitable for large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005084714810000091
    Figure BDA0005084714810000091
  • Figure BDA0005084714810000092
    Figure BDA0005084714810000092
  • Figure BDA0005084714810000101
    Figure BDA0005084714810000101
Patent Text Reader

Abstract

The invention provides a valaciclovir hydrochloride tablet and a preparation method thereof, and the valaciclovir hydrochloride tablet comprises the following raw materials in parts by weight: 110 to 150 parts of valaciclovir hydrochloride, 15 to 20 parts of a polyaspartic acid-glutathione cross-linked compound, 10 to 15 parts of cross-linked povidone XL-10, 8 to 10 parts of colloidal silicon dioxide, 10 to 15 parts of microcrystalline cellulose 101 and 5 to 8 parts of magnesium stearate. And 10-13 parts of a medicinal film coating premix. The valaciclovir hydrochloride tablet disclosed by the invention is short in disintegration time, can be quickly dissolved out, almost realizes complete dissolution within 15 minutes, and reduces the impurity contents of acyclovir and guanine. The stability is good, the accelerated stability dissolution does not have the tendency of slowing down, the production process is simple, and the requirements of large-scale production are met. The valaciclovir hydrochloride is coated in a polyaspartic acid-glutathione cross-linked compound, so that the influence of excessive moisture on the crystal form of the valaciclovir hydrochloride is avoided, the moisture of particles is controlled, the hydrolysis of the valaciclovir hydrochloride is limited to the greatest extent, and the stability of the valaciclovir hydrochloride is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a valacyclovir hydrochloride tablet and a preparation method thereof. Background Art

[0002] Valacyclovir hydrochloride, molecular formula: C 13 H 20 N6O4·HCl, valacyclovir is a prodrug of acyclovir. It is rapidly absorbed after oral administration and quickly converted into acyclovir in the body. Its antiviral effect is exerted by acyclovir. After acyclovir enters herpes infected cells, it competes with deoxynucleoside for viral thymidine kinase or cell kinase. The drug is phosphorylated into activated acyclosine triphosphate, which competes with deoxyguanine triphosphate for viral DNA polymerase as a substrate for viral DNA replication, thereby inhibiting viral DNA synthesis and showing antiviral efficacy. Valacyclovir hydrochloride has high oral bioavailability and better antiviral activity in vivo than acyclovir.

[0003] At present, the preparation methods of valacyclovir hydrochloride mainly include: preparing samples using dry granulation process and preparing samples using wet granulation process. Among them, valacyclovir hydrochloride prepared by dry granulation process has poor viscosity, the proportion of raw materials in the tablet prescription is high, the granules extruded by dry granulation are poorly formed, and there are many small-sized particles and fine powders, which are difficult to meet the compressibility requirements of commercial production tablets. Valacyclovir hydrochloride prepared by wet granulation process often has poor stability and complicated procedures, which is not conducive to large-scale production.

[0004] However, valacyclovir hydrochloride is easy to absorb moisture during storage and is easily degraded to form acyclovir, so hydrolysis needs to be limited and stability needs to be improved. At the same time, the inventors also found that the accelerated stability dissolution of valacyclovir hydrochloride tends to slow down. Therefore, it is necessary to develop a valacyclovir hydrochloride tablet that can dissolve quickly and improve stability. Summary of the invention

[0005] In view of this, the present invention provides a valacyclovir hydrochloride tablet and a preparation method thereof.

[0006] The technical solution of the present invention is achieved in this way:

[0007] A valacyclovir hydrochloride tablet comprises the following raw materials in parts by weight: 110-150 parts of valacyclovir hydrochloride, 15-20 parts of polyaspartic acid-glutathione cross-linked complex, 10-15 parts of cross-linked polyvinylpyrrolidone XL-10, 8-10 parts of colloidal silicon dioxide, 10-15 parts of microcrystalline cellulose 101, 5-8 parts of magnesium stearate, and 10-13 parts of a medicinal film coating premix.

[0008] Furthermore, the preparation method of the polyaspartic acid-glutathione cross-linked complex comprises: adding polyaspartic acid and glutathione into a phosphate buffer, and ultrasonically treating to obtain the polyaspartic acid-glutathione cross-linked complex.

[0009] Furthermore, the mass ratio of the polyaspartic acid to glutathione is 2-4:1; the concentration of the phosphate buffer is 0.01-0.05 mol / L; and the solid-liquid ratio of the polyaspartic acid to the phosphate buffer is 1:4-6 g / mL.

[0010] Furthermore, the ultrasonic treatment is carried out at 200-300 rpm and 50-60° C. for 60-90 min.

[0011] A method for preparing valacyclovir hydrochloride tablets, the specific steps comprising:

[0012] (1) adding the polyaspartic acid-glutathione cross-linked complex into a phosphate buffer, adding valacyclovir hydrochloride and stirring to obtain a suspension, i.e., valacyclovir hydrochloride coated with the polyaspartic acid-glutathione cross-linked complex;

[0013] (2) adding 20-30 wt % of cross-linked polyvinylpyrrolidone XL-10 to the suspension in step (1), ultrasonically treating, spray granulating, drying, and sieving to obtain granules I;

[0014] (3) Adding Granules I into purified water, adding 20-30 wt% of cross-linked polyvinylpyrrolidone XL-10, mixing evenly, performing secondary spray granulation, drying, and sieving to obtain Granules II;

[0015] (4) mixing particles II and colloidal silicon dioxide to obtain particles III;

[0016] (5) Add Granule III, microcrystalline cellulose 101, and the remaining amount of cross-linked polyvinylpyrrolidone XL-10 into a mixing granulator, and continue to add magnesium stearate to mix, press into tablets, and coat with a pharmaceutical film coating premix to obtain valacyclovir hydrochloride tablets.

[0017] Furthermore, in step (1), the concentration of the phosphate buffer is 0.01-0.05 mol / L; and the solid-liquid ratio of the polyaspartic acid-glutathione cross-linked complex to the phosphate buffer is 1:8-10 g / mL.

[0018] Furthermore, in step (2), the ultrasonic treatment is carried out at 20-30kHz and 20-25°C for 30-60s; the spray granulation pressure is 1-3bar, the flow rate is 5-10mL / min, the temperature is 20-30°C, and the time is 1-3min;

[0019] Furthermore, in step (2), the drying temperature is 40-50° C. and the drying time is 2-4 hours; and the screening is through 60-80 mesh.

[0020] Furthermore, in step (3), the solid-liquid ratio of the particles I to purified water is 1:4-6 g / mL; the secondary spraying is performed at a pressure of 1-3 bar, a temperature of 20-25° C., a flow rate of 5-8 mL / min, a spray distance of 5-10 cm, and granulation for 30-60 seconds; the drying is performed at 40-50° C. for 2-4 hours, and the moisture content is controlled at 2%-5%; and the screening is performed through 80-100 mesh.

[0021] Furthermore, in step (5), the tabletting pressure is 10-20 MPa and the rotation speed is 10-20 rpm.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] 1. The valacyclovir hydrochloride tablets of the present invention encapsulate valacyclovir hydrochloride in a polyaspartic acid-glutathione cross-linked complex, which can protect valacyclovir hydrochloride from oxidation and degradation, improve its stability, and extend the shelf life. Polyaspartic acid is a natural polymer with good biocompatibility and improved safety. The polyaspartic acid-glutathione cross-linked complex can improve the solubility and absorption rate of valacyclovir hydrochloride, improve bioavailability, and enhance efficacy.

[0024] 2. The present invention first coats valacyclovir hydrochloride in a polyaspartic acid-glutathione cross-linked complex and then granulates it, thereby reducing the excessive contact between valacyclovir hydrochloride and water, avoiding the influence of excessive water on the crystal form of valacyclovir hydrochloride, controlling the water content of the particles, limiting the hydrolysis of valacyclovir hydrochloride to the greatest extent, improving the stability of valacyclovir hydrochloride, improving the fluidity of the particles, and increasing the yield.

[0025] 3. The valacyclovir hydrochloride tablets of the present invention do not need to add disintegrants, but have a short disintegration time, can be rapidly dissolved, and almost completely dissolved within 15 minutes, and the impurity contents of acyclovir and guanine are reduced. The stability is good, the accelerated stability dissolution does not have a slowing trend, the total impurity content does not change significantly, the production process is simple, and meets the requirements of large-scale production. DETAILED DESCRIPTION

[0026] In order to better understand the technical content of the present invention, specific embodiments are provided below to further illustrate the present invention.

[0027] Unless otherwise specified, the experimental methods used in the embodiments of the present invention are all conventional methods.

[0028] Unless otherwise specified, the materials, reagents, etc. used in the embodiments of the present invention can be obtained from commercial sources.

[0029] The medicinal film coating premix of the present invention was purchased from Guangzhou Kafen Biotechnology Co., Ltd.

[0030] The cross-linked polyvinylpyrrolidone XL-10 of the present invention was purchased from Shanghai Dexiang Pharmaceutical Technology Co., Ltd.

[0031] Example 1

[0032] A valacyclovir hydrochloride tablet comprises the following raw materials in parts by weight: 130 parts of valacyclovir hydrochloride, 18 parts of polyaspartic acid-glutathione cross-linked complex, 13 parts of cross-linked polyvinylpyrrolidone XL-10, 9 parts of colloidal silicon dioxide, 13 parts of microcrystalline cellulose 101, 7 parts of magnesium stearate, and 11 parts of medicinal film coating premix.

[0033] Preparation of polyaspartic acid-glutathione cross-linked complex: Polyaspartic acid and glutathione (mass ratio of 3:1) were added to 0.03 mol / L phosphate buffer at a solid-liquid ratio of 1:5 g / mL, and ultrasonically treated at 250 rpm and 55°C for 75 min to obtain a polyaspartic acid-glutathione cross-linked complex.

[0034] The preparation method of the above-mentioned valacyclovir hydrochloride tablets specifically comprises the following steps:

[0035] (1) adding the polyaspartic acid-glutathione cross-linked complex to a 0.03 mol / L phosphate buffer at a solid-liquid ratio of 1:9 g / mL, adding valacyclovir hydrochloride and stirring to obtain a suspension, i.e., valacyclovir hydrochloride coated with the polyaspartic acid-glutathione cross-linked complex;

[0036] (2) adding 25 wt% of cross-linked polyvinylpyrrolidone XL-10 to the suspension in step (1), ultrasonically treating at 25 kHz and 23° C. for 45 s, spray granulating (pressure 2 bar, flow rate 8 mL / min, temperature 25° C.) for 2 min, drying at 45° C. for 3 h, and sieving (70 mesh) to obtain granules I;

[0037] (3) According to the solid-liquid ratio of 1:5 g / mL, granules I were added to purified water, 25 wt% of cross-linked polyvinylpyrrolidone XL-10 was added, mixed evenly, and subjected to secondary spray granulation (pressure 2 bar, temperature 22°C, flow rate 7 mL / min, distance 8 cm) for 45 s, dried at 45°C for 3 h, the moisture content was controlled to 3%, and sieved (through 90 mesh) to obtain granules II;

[0038] (4) mixing particles II and colloidal silicon dioxide to obtain particles III;

[0039] (5) Add Granule III, microcrystalline cellulose 101, and the remaining amount of cross-linked polyvinylpyrrolidone XL-10 into a mixing granulator, and continue to add magnesium stearate and mix. Tablets are pressed (15 MPa, 15 rpm), and coated with a pharmaceutical film coating premix to obtain valacyclovir hydrochloride tablets.

[0040] Example 2

[0041] A valacyclovir hydrochloride tablet comprises the following raw materials in parts by weight: 110 parts of valacyclovir hydrochloride, 15 parts of polyaspartic acid-glutathione cross-linked complex, 10 parts of cross-linked polyvinylpyrrolidone XL-10, 8 parts of colloidal silicon dioxide, 10 parts of microcrystalline cellulose 101, 5 parts of magnesium stearate, and 10 parts of medicinal film coating premix.

[0042] Preparation of polyaspartic acid-glutathione cross-linked complex: Polyaspartic acid and glutathione (mass ratio of 2:1) were added to 0.01 mol / L phosphate buffer at a solid-liquid ratio of 1:4 g / mL, and ultrasonically treated at 200 rpm and 50°C for 60 min to obtain a polyaspartic acid-glutathione cross-linked complex.

[0043] The preparation method of the above-mentioned valacyclovir hydrochloride tablets specifically comprises the following steps:

[0044] (1) adding the polyaspartic acid-glutathione cross-linked complex to a 0.01 mol / L phosphate buffer at a solid-liquid ratio of 1:8 g / mL, adding valacyclovir hydrochloride and stirring to obtain a suspension, i.e., valacyclovir hydrochloride coated with the polyaspartic acid-glutathione cross-linked complex;

[0045] (2) adding 20 wt % of cross-linked polyvinylpyrrolidone XL-10 to the suspension in step (1), ultrasonically treating at 20 kHz and 20° C. for 30 s, spray granulating (pressure 1 bar, flow rate 5 mL / min, temperature 20° C.) for 1 min, drying at 40° C. for 2 h, and sieving (60 mesh) to obtain granules I;

[0046] (3) According to the solid-liquid ratio of 1:4 g / mL, granules I were added to purified water, 20 wt% of cross-linked polyvinylpyrrolidone XL-10 was added, mixed evenly, and subjected to secondary spray granulation (pressure 1 bar, temperature 20°C, flow rate 5 mL / min, distance 5 cm) for 30 s, dried at 40°C for 2 h, the moisture content was controlled to 2%, and sieved (passed through 80 mesh) to obtain granules II;

[0047] (4) mixing particles II and colloidal silicon dioxide to obtain particles III;

[0048] (5) Add Granule III, microcrystalline cellulose 101, and the remaining amount of cross-linked polyvinylpyrrolidone XL-10 into a mixing granulator, and continue to add magnesium stearate and mix. Tablets are pressed (10 MPa, 10 rpm), and coated with a pharmaceutical film coating premix to obtain valacyclovir hydrochloride tablets.

[0049] Example 3

[0050] A valacyclovir hydrochloride tablet comprises the following raw materials in parts by weight: 150 parts of valacyclovir hydrochloride, 20 parts of polyaspartic acid-glutathione cross-linked complex, 15 parts of cross-linked polyvinylpyrrolidone XL-10, 10 parts of colloidal silicon dioxide, 15 parts of microcrystalline cellulose 101, 8 parts of magnesium stearate, and 13 parts of medicinal film coating premix.

[0051] Preparation of polyaspartic acid-glutathione cross-linked complex: Polyaspartic acid and glutathione (mass ratio of 4:1) were added to 0.05 mol / L phosphate buffer at a solid-liquid ratio of 1:6 g / mL, and ultrasonically treated at 300 rpm and 60°C for 90 min to obtain a polyaspartic acid-glutathione cross-linked complex.

[0052] The preparation method of the above-mentioned valacyclovir hydrochloride tablets specifically comprises the following steps:

[0053] (1) adding the polyaspartic acid-glutathione cross-linked complex to a 0.05 mol / L phosphate buffer at a solid-liquid ratio of 1:10 g / mL, adding valacyclovir hydrochloride and stirring to obtain a suspension, i.e., valacyclovir hydrochloride coated with the polyaspartic acid-glutathione cross-linked complex;

[0054] (2) adding 30 wt % of cross-linked polyvinylpyrrolidone XL-10 to the suspension in step (1), ultrasonically treating at 30 kHz and 25° C. for 60 s, spray granulating (pressure 3 bar, flow rate 10 mL / min, temperature 30° C.) for 3 min, drying at 50° C. for 4 h, and sieving (passing 80 mesh) to obtain granules I;

[0055] (3) According to the solid-liquid ratio of 1:6 g / mL, granules I were added to purified water, 30 wt% of cross-linked polyvinylpyrrolidone XL-10 was added, mixed evenly, and subjected to secondary spray granulation (pressure 3 bar, temperature 25°C, flow rate 8 mL / min, distance 10 cm) for 60 s, dried at 50°C for 4 h, the moisture content was controlled to 5%, and sieved (passing 100 mesh) to obtain granules II;

[0056] (4) mixing particles II and colloidal silicon dioxide to obtain particles III;

[0057] (5) Add Granule III, microcrystalline cellulose 101, and the remaining amount of cross-linked polyvinylpyrrolidone XL-10 into a mixing granulator, and continue to add magnesium stearate and mix. Tablets are pressed (20 MPa, 20 rpm), and coated with a pharmaceutical film coating premix to obtain valacyclovir hydrochloride tablets.

[0058] Comparative Example 1

[0059] The difference from Example 1 is that the polyaspartic acid-glutathione cross-linked complex is replaced by povidone K90, and the rest is the same as Example 1.

[0060] That is, the valacyclovir hydrochloride tablets of this comparative example include the following raw materials in parts by weight: 130 parts of valacyclovir hydrochloride, 18 parts of povidone K90, 13 parts of cross-linked polyvinylpyrrolidone XL-10, 9 parts of colloidal silicon dioxide, 13 parts of microcrystalline cellulose 101, 7 parts of magnesium stearate, and 11 parts of pharmaceutical film coating premix.

[0061] The valacyclovir hydrochloride tablets of this comparative example are prepared by the following method:

[0062] (1) valacyclovir hydrochloride, povidone K90, and 25 wt% of cross-linked povidone XL-10 are mixed to obtain a mixed material I;

[0063] (2) According to the solid-liquid ratio of 1:5 g / mL, the mixed material I was added to purified water, and 25 wt% of cross-linked polyvinylpyrrolidone XL-10 was added, mixed evenly, and spray granulated (pressure 2 bar, temperature 22° C., flow rate 7 mL / min, distance 8 cm) for 45 s, dried at 45° C. for 3 h, the moisture content was controlled to 3%, and sieved (through 90 mesh) to obtain a mixed material II;

[0064] (3) mixing and granulating the mixed material II and colloidal silicon dioxide to obtain a mixed material III;

[0065] (4) Add the mixed material III, microcrystalline cellulose 101, and the remaining amount of cross-linked polyvinylpyrrolidone XL-10 into a mixing granulator and mix, continue to add magnesium stearate and mix, press into tablets (15 MPa, 15 rpm), and coat with a medicinal film coating premix to obtain valacyclovir hydrochloride tablets.

[0066] Comparative Example 2

[0067] The difference from Example 1 is that the preparation process uses only one spray granulation, and the rest is consistent with Example 1.

[0068] The valacyclovir hydrochloride tablets of this comparative example are prepared by the following method:

[0069] (1) adding the polyaspartic acid-glutathione cross-linked complex to a 0.03 mol / L phosphate buffer at a solid-liquid ratio of 1:9 g / mL, adding valacyclovir hydrochloride and stirring to obtain a suspension, i.e., valacyclovir hydrochloride coated with the polyaspartic acid-glutathione cross-linked complex;

[0070] (2) adding 25 wt% of cross-linked polyvinylpyrrolidone XL-10 to the suspension in step (1), ultrasonically treating at 25 kHz and 23° C. for 45 s, spray granulating (pressure 2 bar, flow rate 8 mL / min, temperature 25° C.) for 2 min, drying at 45° C. for 3 h, controlling the moisture content to 3%, and sieving (passing 90 mesh) to obtain granules I;

[0071] (3) mixing particles I and colloidal silicon dioxide to obtain particles II;

[0072] (4) Add Granule II, microcrystalline cellulose 101, and the remaining amount of cross-linked polyvinylpyrrolidone XL-10 into a mixing granulator and mix, continue to add magnesium stearate and mix, press into tablets (15 MPa, 15 rpm), and coat with a pharmaceutical film coating premix to obtain valacyclovir hydrochloride tablets.

[0073] Comparative Example 3

[0074] The difference from Example 1 is that the preparation process uses traditional dry granulation, and the rest is consistent with Example 1.

[0075] The valacyclovir hydrochloride tablets of this comparative example are prepared by the following method:

[0076] valacyclovir hydrochloride, polyaspartic acid-glutathione cross-linked complex, cross-linked polyvinylpyrrolidone XL-10, colloidal silicon dioxide, microcrystalline cellulose 101, and magnesium stearate are uniformly mixed, dry granulated by a tablet press (pressure 20 MPa), sieved (through 90 mesh), tabletted (15 MPa, 15 rpm), and coated with a medicinal film coating premix to obtain valacyclovir hydrochloride tablets.

[0077] Comparative Example 4

[0078] The difference from Example 1 is that the preparation process uses traditional wet granulation, and the rest is consistent with Example 1.

[0079] The valacyclovir hydrochloride tablets of this comparative example are prepared by the following method:

[0080] (1) mixing valacyclovir hydrochloride, polyaspartic acid-glutathione cross-linked complex, crospovidone XL-10, colloidal silicon dioxide, microcrystalline cellulose 101 and magnesium stearate to obtain a mixed material;

[0081] (2) spraying purified water into the mixture at a solid-liquid ratio of 1:5 g / mL to form wet granules;

[0082] (3) The wet granules were sieved (through a 4×4 mm square hole sieve), dried at 45° C. for 3 h, the moisture content was controlled to 3%, tableted (15 MPa, 15 rpm), and coated with a pharmaceutical film coating premix to obtain valacyclovir hydrochloride tablets.

[0083] Test Case

[0084] 1. Disintegration time limit

[0085] Take 6 tablets of the test sample, start the disintegration instrument for inspection, and all tablets should be completely disintegrated within 15 minutes. If one tablet cannot be completely disintegrated, another 6 tablets should be taken for retesting, and all should meet the requirements. Record the complete disintegration time of the valacyclovir hydrochloride tablets prepared in Examples 1-3 and Comparative Examples 1-4. The results are recorded in Table 1.

[0086] 2. Dissolution

[0087] According to the dissolution and release determination method of the Chinese Pharmacopoeia (2015 edition of Part IV General Rules 0931 Method II), the valacyclovir hydrochloride tablets prepared in Examples 1-3 and Comparative Examples 1-4 were tested for dissolution.

[0088] Specific method: Take pH=1.0 hydrochloric acid solution as dissolution medium, rotate at 50rpm, operate according to the law, take 10ml of solution after 5min, 10min, and 15min, filter, accurately measure the appropriate amount of filtrate, and quantitatively dilute with pH=1.0 hydrochloric acid solution to make a solution containing about 10μg per 1ml. According to the ultraviolet visible spectrophotometry (Appendix IV A), immediately measure the absorbance at a wavelength of 254nm; take an appropriate amount of valacyclovir hydrochloride reference substance, accurately weigh it, dissolve it with pH=1.0 hydrochloric acid solution and quantitatively dilute it to make a solution containing about 10μg per 1ml, measure it in the same way, and calculate the dissolution amount of each tablet. The limit is 85% of the labeled amount, which should meet the regulations. The results are recorded in Table 1.

[0089] 3. Content test

[0090] Determine according to the high performance liquid chromatography method (Appendix VD). For the chromatographic conditions and system suitability test, use octadecylsilane bonded silica gel as the filler; methanol-water (10:90) as the mobile phase; the detection wavelength is 254 nm. Take 5 ml of the valacyclovir hydrochloride reference solution, add 1 ml of the guanine reference stock solution under the item of guanine and other related substances, shake well, take 20 μl and inject it into the liquid chromatograph, record the chromatogram, and the separation degree between the valacyclovir hydrochloride peak and the guanine peak should meet the requirements.

[0091] Determination method: Take about 50 mg of the valacyclovir hydrochloride tablets prepared in Examples 1-3 and Comparative Examples 1-4, accurately weigh, place in a 50 ml volumetric flask, add 5 ml of 0.4% sodium hydroxide solution to dissolve, dilute with water to scale, shake well, accurately measure 2 ml, place in a 100 ml volumetric flask, dilute with water to scale, shake well, accurately measure 20 μl, inject into a liquid chromatograph, and record the chromatogram; take an appropriate amount of valacyclovir hydrochloride reference substance, and determine in the same way. Calculate by peak area according to the external standard method to obtain the content. The content results are recorded in Table 1.

[0092] 4. Impurities

[0093] Accurately weigh an appropriate amount of fine powder under the content determination item, add 0.01 mol / L potassium dihydrogen phosphate solution (adjust pH=3.0 with phosphoric acid) to dissolve valacyclovir hydrochloride and dilute to the scale, shake well, filter, and take the filtrate as the test solution. Acyclovir should not exceed 0.5%. The results of the content of related impurities (acyclovir, guanine) are recorded in Table 1.

[0094] 5. Accelerated testing

[0095] The valacyclovir hydrochloride tablets prepared in Example 1 were placed at a temperature of 40°C ± 2°C and a relative humidity of 75% ± 5% for 6 months, and samples were taken to test the dissolution, total impurities and content. The data are recorded in Table 2.

[0096] Table 1

[0097]

[0098] Table 2

[0099]

[0100]

[0101] As can be seen from Table 1, compared with Comparative Examples 1-4, the valacyclovir hydrochloride tablets prepared in Examples 1-3 of the present invention can significantly shorten the disintegration time and can dissolve quickly, almost completely dissolving within 15 minutes. The impurity contents of acyclovir and guanine are reduced.

[0102] As can be seen from Table 2, the stability of the valacyclovir hydrochloride tablets prepared in Examples 1-3 is good, there is no trend of slowing down in the accelerated stability dissolution, and the content of total impurities has no obvious change. However, the performance of the valacyclovir hydrochloride tablets of Comparative Examples 1-4 is reduced, the dissolution rate is significantly reduced, and the total impurity content is increased.

[0103] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A valacyclovir hydrochloride tablet, characterized in that: The invention comprises the following raw materials in parts by weight: 110-150 parts of valacyclovir hydrochloride, 15-20 parts of polyaspartic acid-glutathione cross-linked complex, 10-15 parts of cross-linked polyvinylpyrrolidone XL-10, 8-10 parts of colloidal silicon dioxide, 10-15 parts of microcrystalline cellulose 101, 5-8 parts of magnesium stearate, and 10-13 parts of medicinal film coating premix.

2. A valacyclovir hydrochloride tablet according to claim 1, characterized in that: The preparation method of the polyaspartic acid-glutathione cross-linked complex comprises: adding polyaspartic acid and glutathione into a phosphate buffer, and ultrasonically treating the polyaspartic acid-glutathione cross-linked complex to obtain the polyaspartic acid-glutathione cross-linked complex.

3. A valacyclovir hydrochloride tablet as claimed in claim 2, characterized in that: The mass ratio of polyaspartic acid to glutathione is 2-4:1; the concentration of the phosphate buffer is 0.01-0.05 mol / L; and the solid-liquid ratio of polyaspartic acid to phosphate buffer is 1:4-6 g / mL.

4. A valacyclovir hydrochloride tablet according to claim 2, characterized in that: The ultrasonic treatment is carried out at 200-300 rpm and 50-60° C. for 60-90 min.

5. The method for preparing valacyclovir hydrochloride tablets according to claim 1, characterized in that: The specific steps include: (1) adding the polyaspartic acid-glutathione cross-linked complex into a phosphate buffer, adding valacyclovir hydrochloride and stirring to obtain a suspension, i.e., valacyclovir hydrochloride coated with the polyaspartic acid-glutathione cross-linked complex; (2) adding 20-30 wt % of cross-linked polyvinylpyrrolidone XL-10 to the suspension in step (1), ultrasonically treating, spray granulating, drying, and sieving to obtain granules I; (3) Adding Granules I into purified water, adding 20-30 wt% of cross-linked polyvinylpyrrolidone XL-10, mixing evenly, performing secondary spray granulation, drying, and sieving to obtain Granules II; (4) mixing particles II and colloidal silicon dioxide to obtain particles III; (5) Add Granule III, microcrystalline cellulose 101, and the remaining amount of cross-linked polyvinylpyrrolidone XL-10 into a mixing granulator, and continue to add magnesium stearate to mix, press into tablets, and coat with a pharmaceutical film coating premix to obtain valacyclovir hydrochloride tablets.

6. The method for preparing valacyclovir hydrochloride tablets according to claim 5, characterized in that: In step (1), the concentration of the phosphate buffer is 0.01-0.05 mol / L; the solid-liquid ratio of the polyaspartic acid-glutathione cross-linked complex to the phosphate buffer is 1:8-10 g / mL.

7. The method for preparing valacyclovir hydrochloride tablets according to claim 5, characterized in that: In step (2), the ultrasonic treatment is carried out at 20-30kHz and 20-25°C for 30-60s; the pressure of the spray granulation is 1-3bar, the flow rate is 5-10mL / min, the temperature is 20-30°C, and the time is 1-3min.

8. The method for preparing valacyclovir hydrochloride tablets according to claim 5, characterized in that: In step (2), the drying temperature is 40-50° C. and the drying time is 2-4 hours; and the screening is through 60-80 mesh.

9. The method for preparing valacyclovir hydrochloride tablets according to claim 5, characterized in that: In step (3), the solid-liquid ratio of the particles I to purified water is 1:4-6 g / mL; the secondary spraying is performed at a pressure of 1-3 bar, a temperature of 20-25° C., a flow rate of 5-8 mL / min, a spray distance of 5-10 cm, and granulation for 30-60 seconds; the drying is performed at 40-50° C. for 2-4 hours, and the moisture content is controlled at 2%-5%; and the screening is performed through 80-100 mesh.

10. The method for preparing valacyclovir hydrochloride tablets according to claim 5, characterized in that: In step (5), the tabletting pressure is 10-20 MPa and the rotation speed is 10-20 rpm.

Citation Information

Patent Citations

  • Valaciclovir hydrochloride fast-release preparation and preparation method thereof

    CN111053748A

  • A compound for the detection of bio-thiols and process for preparation thereof

    IN201811004909A

  • Exudation of content in microorganism

    JP1991254675A

  • Production of crosslinked polysuccinimide

    JP1999158267A

  • Process for preparing ethylcellulose microcapsules

    US4486471A